Evaluating The Effectiveness Of Eyemax Mono Iol For Enhancing Vision In Mild To Moderate Age-Related Macular Degeneration.
Published 2024 - 42nd Congress of the ESCRS
Reference: PP22.15 | Type: Free paper | DOI: 10.82333/gm0r-1894
Authors: Johan Lønsmann Poulsen 1 , Jacob Nielsen* 2 , Niels Vesti Nielsen 3
1ØJENHOSPITALET DANMARK,Charlottelund,Denmark, 2Øjenhospitalet,Charlottenlund,Denmark, 3ØJENHOSPITALET DANMARK,Charlottenlund,Denmark
Purpose
This study aims to assess the safety and effectiveness of the EyeMax Mono intraocular lens (IOL) (SharpView Ophthalmology, London, UK) for patients with mild to moderate age-related macular degeneration (AMD). Specifically, it focuses on the ability of this extended macular vision IOL to improve retinal images within 10 degrees of retinal eccentricity, thereby enhancing visual outcomes for those affected by AMD.
Setting
A private medical centre in Denmark.
Methods
This study employed a retrospective analysis at a single center, targeting patients with mild to moderate age-related macular degeneration (AMD) who received the EyeMax Mono intraocular lens (IOL) after undergoing cataract surgery. The EyeMax Mono IOL, a hydrophobic acrylic single-piece lens, is specially designed to enhance macular vision. Participants were categorized based on the severity of their AMD. Key evaluation metrics included intraoperative and postoperative complications, changes in the postoperative spherical equivalent, and comparisons of corrected distance visual acuity (CDVA) before and after the implantation
Results
The study included 22 eyes of 17 patients (15 eyes with mild AMD and 7 eyes with moderate AMD). Following the EyeMax Mono IOL implantation, the average postoperative spherical equivalent was 1.27±1.2D. CDVA (logMAR) showed significant improvement, with preoperative scores at 0.43±0.23 (n=22) improving to 0.34±0.25 (n=20) postoperatively (p<0.001). None of the eyes experienced a loss of more than one line of CDVA; 9 eyes (40.9%) saw an improvement of more than one line in CDVA, and 3 eyes (13.6%) improved by three lines. The average CDVA gain was 0.11 in the mild AMD group (n=13) and 0.07 in the moderate AMD group (n=7). No intraoperative or postoperative complications were reported.
Conclusions
The EyeMax Mono intraocular lens (IOL) has proven to be both safe and efficacious in enhancing corrected distance visual acuity (CDVA) for patients with age-related macular degeneration (AMD), demonstrating particular benefit in those with mild AMD. This study underscores the potential of the EyeMax Mono IOL as a viable intervention for improving visual outcomes in individuals affected by mild to moderate AMD.